Trial Profile
An Open Label Study With OHR/AVR118 in Advanced Cancer Patients with Anorexia-Cachexia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs AVR 118 (Primary)
- Indications Anorexia; Cachexia
- Focus Therapeutic Use
- 26 Mar 2013 Results have been reported in an Ohr Pharmaceutical media release.
- 21 Mar 2013 Primary endpoint 'Bodyweight' (weight gain) has not been met according to an Ohr Pharmaceutical media release.
- 26 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.